In cancer research, Dr. Clay Siegall is leading by example. The guy has a resume of success that extends back over 20 years. Siegall is the CEO of Seattle Genetics, which is a biotech company that specializes in the production of antibody-based therapies. Siegall is known all throughout the medical industry, and he is a man of many titles. In other words, he’s known to be a scientist, a doctor, a mentor and a businessman. The George Washington University graduate has worked with numerous medical organizations and pharmaceutical companies over the years such as Bayer and the National Institute of Health.
Seattle Genetics is one of the leading cancer research institutions in the world. It’s located in Seattle, Washington, and it has well-over 1,000 employees. The company’s top drug, ADCETRIS, is one of the very best cancer fighting medications in history. This is targeted treatment at its finest. ADCETRIS attacks cancerous cells within the body then gives it a cell-killing blow. On top of that, the good cells in the body aren’t harmed, which drastically cuts down on side effects. Siegall began this journey many years ago and the illness for one of his family members directed him into this field of work. He is very familiar with how cancer destroys the body over time and this is what fuels his passion. He is a natural-born philanthropist in a sense.
Seattle Genetics is a multimillion dollar organization, but it didn’t become profitable until about 10 years after its IPO. In the company’s earlier days, funds were being depleted left and right. This is a very demanding industry, but it showed Siegall that he had to work even more harder. As of today, the success of Seattle Genetics isn’t by chance, but rather by intuitive design.
Advanced therapies have changed the game when it comes to fighting cancer. Unlike the cancer fighting medications of the past, these therapies won’t harm any of the good cells in the body, which drastically cuts down on unwanted side effects. Seattle Genetics of Bothell, Washington, produces some of the best advanced therapies of today. They’re known as antibody-based therapies, but they are broken down into antibody drug conjugates. ADCETRIS, Seattle Genetics’ top antibody drug conjugate, is the leader of the pack thanks to Dr. Clay Siegall. Siegall is the president and the CEO of Seattle Genetics. He has been able to distribute the medications through strategic licensing deals. GlaxoSmithKline, Pfizer and Genentech have the rights of distribution. With this deal, the medications are now being used all across the globe in about 65 different countries.
Siegall has done a spectacular job with his leadership role. The guy’s educational background is very broad. He has a B.S. in Zoology and a Ph.D in Genetics. To add insult to injury, Siegall is the current holder of 15 patents, and he has written up to 70 publications. On top of that, he is also the winner of many philanthropic awards. Cancer’s deadly wrath has claimed many lives throughout the years. This disease can manifest in various organs within the body. Siegall has experienced this first-hand as his father suffered with the disease for many years. At the time, there wasn’t much in the form of advancements and this is what flamed the passion for Siegall.
Seattle Genetics has grown at an alarming rate since its inception in 1998. The company has many more advanced drugs in the pipeline, which will be released sometime in the future. Siegall’s dedication, perseverance and ambition can’t be questioned, and he has a long list of happy patients who will testify on his behalf.